Amgen’s MariTide to be tested in multiple obesity-related indications at PhIII

Amgen offered a glance at plans for its obesity drug candidate MariTide during its fourth-quarter earnings call, including the extension of an ongoing Phase II trial and a Phase III development pathway spanning multiple indications. But the company kept the finer details close to its chest.

MariTide comprises two GLP-1…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks